20 | Clinical application of the new global definition of acute respiratory distress syndrome in a case of fat embolism syndrome
Emergency Care Journal · 15.07.2026 · 22 (S1)
DOI: 10.4081/ecj.2026.15960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Emergency Care Journal, online erschienen am 15.07.2026. Verfasst von Emanuele Rollo und 12 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The new global definition of Acute Respiratory Distress Syndrome (ARDS) allows diagnosis in patients receiving High-Flow Nasal Cannula (HFNC) therapy at flow rates ≥30 L/min and supports the SpO2/FiO2 (S/F) ratio as an alternative to the PaO2/FiO2 (P/F) ratio. It also recognizes Lung Ultrasound (LUS) as an imaging modality equivalent to CT or chest X-ray for identifying bilateral opacities, emphasizing its value for dynamic bedside monitoring of disease progression and recovery. We report a case of Fat Embolism Syndrome (FES) evolving into moderate ARDS, managed exclusively with HFNC and monitored through an integrated ultrasonographic approach.
Methods
A 16-year-old male was admitted to the Intensive Care Unit (ICU) for hypoxemia that developed after a post-traumatic diaphyseal femur fracture. On admission, on spontaneous ventilation before the initiation of HFNC, the S/F ratio was 224. Chest CT revealed bilateral alveolar infiltrates consistent with ARDS. HFNC was started (initial flow 55 L/min, FiO₂ 0.5), with serial monitoring of P/F and S/F ratios. A systematic 8-zone diagnostic lung ultrasound was also performed with a convex low frequency probe and the lung ultrasound computed for each zone.
Results
Following HFNC initiation, oxygenation progressively improved. The P/F ratio increased from 138 to 262 mmHg, while the S/F ratio rose from 186 to 306, with parallel trajectories accompanying the gradual reduction of support (Figure 1) and the HFNC flow was decreased from 60 to 40 L/min in accordance with clinical and gasometric improvement. Lung ultrasound demonstrated a distinct interstitial pattern with multiple B-lines with a global LUS score of 14, consistent with CT and chest X-ray findings (Figure 2). The clinical course was favorable, with complete HFNC weaning by day 5 and discharge on day 6.
Conclusions
Implementation of the new global definition is especially useful in post-traumatic ARDS in young patients, for whom a tube-sparing strategy is encouraged - and in resource-limited settings with restricted access to blood gas analysis and imaging. Benefits are also envisaged in terms of limiting serial arterial blood gas sampling and iatrogenic anemia in the ICU. This case exemplifies its practical application, showing how integrating HFNC, S/F ratio, and lung ultrasound enables early diagnosis and effective non-invasive management.
Zitieren
APA
Rollo, E., Difonzo, M., Bavaro, G., Carpaneto, D., Laterza, C., Zimatore, C., Ferrara, P., Maringelli, G., Perrini, M., Ribezzi, M., Pisani, L., Grasso, S., & Ranieri, M. V. (2026). 20 | Clinical application of the new global definition of acute respiratory distress syndrome in a case of fat embolism syndrome. Emergency Care Journal, 22(S1). https://doi.org/10.4081/ecj.2026.15960
Vancouver
Rollo E, Difonzo M, Bavaro G, Carpaneto D, Laterza C, Zimatore C, et al. 20 | Clinical application of the new global definition of acute respiratory distress syndrome in a case of fat embolism syndrome. Emergency Care Journal. 2026;22(S1). doi:10.4081/ecj.2026.15960
BibTeX
@article{Rollo2026,
author = {Rollo, Emanuele and Difonzo, Marco and Bavaro, Giuseppe and Carpaneto, Diana and Laterza, Claudio and Zimatore, Claudio and Ferrara, Pasquale and Maringelli, Giovanni and Perrini, Michele and Ribezzi, Mario and Pisani, Luigi and Grasso, Salvatore and Ranieri, Marco V.},
title = {20 | Clinical application of the new global definition of acute respiratory distress syndrome in a case of fat embolism syndrome},
journal = {Emergency Care Journal},
year = {2026},
volume = {22},
number = {S1},
doi = {10.4081/ecj.2026.15960}
}
EUVIMED